Cargando…

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants

The wide transmission and host adaptation of SARS-CoV-2 have led to the rapid accumulation of mutations, posing significant challenges to the effectiveness of vaccines and therapeutic antibodies. Although several neutralizing antibodies were authorized for emergency clinical use, convalescent patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Xiaojing, Zhang, Xinhui, Pan, Shengnan, Yu, Yanying, Shi, Yujin, Lin, Tianli, Duan, Huarui, Liu, Xiuying, Chen, Wenfang, Yang, Xuehua, Chen, Lan, Dong, Xiaoqian, Ren, Lili, Ding, Qiang, Wang, Jianwei, Yang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828845/ https://www.ncbi.nlm.nih.gov/pubmed/35140196 http://dx.doi.org/10.1038/s41392-022-00912-4

Ejemplares similares

Recombinant Full-Length Hepatitis C Virus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies
por: Lin, Tianli, et al.
Publicado: (2022)

Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
por: Yang, Xuehua, et al.
Publicado: (2023)

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
por: Schoof, Michael, et al.
Publicado: (2020)

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
por: Pymm, Phillip, et al.
Publicado: (2022)

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies
por: Miersch, Shane, et al.
Publicado: (2022)

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models
por: Fan, Jiansheng, et al.
Publicado: (2021)

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
por: Wagner, Teresa R, et al.
Publicado: (2021)

Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus
por: Banerjee, Avik, et al.
Publicado: (2022)

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
por: Rujas, Edurne, et al.
Publicado: (2021)

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
por: Cho, Hyeseon, et al.
Publicado: (2021)

The upcoming synthetic ultrapotent opioid wave as a foreseeable disaster
por: Krausz, R Michael, et al.
Publicado: (2022)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
por: Lu, Qizhong, et al.
Publicado: (2021)

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19
por: Esparza, Thomas J., et al.
Publicado: (2022)

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19
por: Esparza, Thomas J., et al.
Publicado: (2021)

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
por: Kaewchim, Kanasap, et al.
Publicado: (2023)

Camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2021)

Novel Vaccine That Blunts Fentanyl Effects and Sequesters Ultrapotent Fentanyl Analogues
por: Barrientos, Rodell C., et al.
Publicado: (2020)

Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH
por: Emmerson, Chris D., et al.
Publicado: (2011)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
por: Yang, Jing, et al.
Publicado: (2023)

Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2022)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance
por: Zou, Jia, et al.
Publicado: (2022)

Click-generated triazole ureas as ultrapotent, in vivo-active serine hydrolase inhibitors
por: Adibekian, Alexander, et al.
Publicado: (2011)

Immobilization of Captive Kulans (Equus hemionus kulan) Without Using Ultrapotent Opioids
por: Bohner, Julia, et al.
Publicado: (2022)

Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4(+) Cancers
por: Cano-Garrido, Olivia, et al.
Publicado: (2021)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiangdong, et al.
Publicado: (2020)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiandong, et al.
Publicado: (2021)

Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains
por: Chen, Chuan, et al.
Publicado: (2022)

A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses
por: Wang, Xiaoyun, et al.
Publicado: (2023)

A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals
por: Wu, Peng, et al.
Publicado: (2022)

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
por: Wang, Lingshu, et al.
Publicado: (2021)

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance
por: Walter, Justin D, et al.
Publicado: (2022)

A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
por: Li, Tingting, et al.
Publicado: (2021)

Characterizing Binding Kinetics and Thermodynamics of Computer-Designed Nanobodies Targeting SARS-CoV-2 RBD
por: Ferraz, Matheus, et al.
Publicado: (2021)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

Structural basis of nanobodies neutralizing SARS-CoV-2 variants
por: Shi, Zhenzhong, et al.
Publicado: (2022)

A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
por: Shi, Sally Yu, et al.
Publicado: (2018)

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
por: Chen, Wei-Hung, et al.
Publicado: (2023)

Excitation of medium spiny neurons by ‘inhibitory’ ultrapotent chemogenetics via shifts in chloride reversal potential
por: Gantz, Stephanie C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p7j80jbsln1kimh0v5obqbbl8s